Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Privitera

Showing results (1-10 of 100) with videos related to

Pageof 10
Sort By:
Tumori|July 9, 2004
Recurrent intracranial hemangiopericytoma with extracranial and unusual multiple metastases: case report and review of the literatureCorrado Spatola, Giuseppe Privitera
Clinical and Translational Medicine|April 29, 2022
Live or let die: Translational insights and clinical perspectives of gasdermin B-dependent intestinal epithelial cell fateGiuseppe Privitera, Theresa T Pizarro
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 14, 2025
What's new in IBD research? Refining the agenda: Outcomes, patient-centered care, and technologyGiuseppe Privitera, Cristina Bezzio, Alessandro Armuzzi
Alimentary Pharmacology & Therapeutics|July 26, 2022
Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease-the IG-IBD LIVE study. Authors' replyDaniela Pugliese, Giuseppe Privitera, Alessandro Armuzzi
Alimentary Pharmacology & Therapeutics|February 18, 2021
Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapyGiuseppe Privitera, Daniela Pugliese, Franco Scaldaferri, et al.
Inflammatory Bowel Diseases|March 11, 2021
Dual Targeted Therapy in Patient With Extensive Crohn's Disease: Different Response at Distinct LocationGiuseppe Privitera, Daniela Pugliese, Alessandro Armuzzi, et al.
Current Medical Research and Opinion|September 27, 2019
Real-word incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitorsDaniela Pugliese, Luisa Guidi, Giuseppe Privitera, et al.
Cancers|February 10, 2024
The Importance of Th2 Immune Responses in Mediating the Progression of Gastritis-Associated Metaplasia to Gastric CancerGiuseppe Privitera, Joseph J Williams, Carlo De Salvo
Nature Reviews. Gastroenterology & Hepatology|February 13, 2023
The gasdermin protein family: emerging roles in gastrointestinal health and diseaseGiuseppe Privitera, Nitish Rana, Alessandro Armuzzi, et al.
Journal of Oncology|January 30, 2010
Antiangiogenic therapy in the treatment of recurrent medulloblastoma in the adult: case report and review of the literatureGiuseppe Privitera, Grazia Acquaviva, Giovanni Carlo Ettorre, et al.
Pageof 10

Showing results (1-10 of 100) with videos related to

Sort By:
Pageof 10
Tumori|July 9, 2004
Recurrent intracranial hemangiopericytoma with extracranial and unusual multiple metastases: case report and review of the literatureCorrado Spatola, Giuseppe Privitera
Clinical and Translational Medicine|April 29, 2022
Live or let die: Translational insights and clinical perspectives of gasdermin B-dependent intestinal epithelial cell fateGiuseppe Privitera, Theresa T Pizarro
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 14, 2025
What's new in IBD research? Refining the agenda: Outcomes, patient-centered care, and technologyGiuseppe Privitera, Cristina Bezzio, Alessandro Armuzzi
Alimentary Pharmacology & Therapeutics|July 26, 2022
Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non-elderly patients with inflammatory bowel disease-the IG-IBD LIVE study. Authors' replyDaniela Pugliese, Giuseppe Privitera, Alessandro Armuzzi
Alimentary Pharmacology & Therapeutics|February 18, 2021
Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapyGiuseppe Privitera, Daniela Pugliese, Franco Scaldaferri, et al.
Inflammatory Bowel Diseases|March 11, 2021
Dual Targeted Therapy in Patient With Extensive Crohn's Disease: Different Response at Distinct LocationGiuseppe Privitera, Daniela Pugliese, Alessandro Armuzzi, et al.
Current Medical Research and Opinion|September 27, 2019
Real-word incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitorsDaniela Pugliese, Luisa Guidi, Giuseppe Privitera, et al.
Cancers|February 10, 2024
The Importance of Th2 Immune Responses in Mediating the Progression of Gastritis-Associated Metaplasia to Gastric CancerGiuseppe Privitera, Joseph J Williams, Carlo De Salvo
Nature Reviews. Gastroenterology & Hepatology|February 13, 2023
The gasdermin protein family: emerging roles in gastrointestinal health and diseaseGiuseppe Privitera, Nitish Rana, Alessandro Armuzzi, et al.
Journal of Oncology|January 30, 2010
Antiangiogenic therapy in the treatment of recurrent medulloblastoma in the adult: case report and review of the literatureGiuseppe Privitera, Grazia Acquaviva, Giovanni Carlo Ettorre, et al.
Pageof 10